Table 2

BCR signaling inhibitors currently in clinical trials in B-cell malignancies

DrugPhase of study
Ibrutinib 3 
GS-1101 3 
Fostamatinib 1/2 
Dasatinib 2 
Sorafenib 2 
AVL-292 1 
Enzastaurin 1 
GDC-0941 1 
XL147 1 
DrugPhase of study
Ibrutinib 3 
GS-1101 3 
Fostamatinib 1/2 
Dasatinib 2 
Sorafenib 2 
AVL-292 1 
Enzastaurin 1 
GDC-0941 1 
XL147 1 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal